Literature DB >> 22526905

Resection of adrenocortical carcinoma liver metastasis: is it justified?

Sébastien Gaujoux1, Hikmat Al-Ahmadie, Peter J Allen, Mithat Gonen, Jinru Shia, Michael D'Angelica, Ronald Dematteo, Yuman Fong, Leslie Blumgart, William R Jarnagin.   

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC) liver metastases (LM) represent a therapeutic challenge, and it is unclear whether resection is justified. This study assesses long-term outcome and prognostic factors after liver resection for metastatic ACC.
METHODS: Patients who underwent resection of ACC LM were identified from institutional databases. Recurrence, survival, and tumor characteristics, including β-catenin and TP53 status based on immunohistochemistry and sequencing, were reviewed. The prognostic value of variables was assessed with log-rank test for univariate analysis and Cox proportional hazard models for multivariate analysis.
RESULTS: From 1978 to 2009, 28 patients (20 females; median age, 45 years), including 11 with synchronous metastasis and 3 with extrahepatic metastasis, underwent resection for ACC LM (major hepatectomy in 61%). Postoperative mortality was nil and morbidity 55%. On pathological examination, tumors were multiple in 68%, with a median size of 43 mm, and resections were R0, 1, and 2 in 59%, 33%, and 7%, respectively. All 28 patients developed recurrent disease, which was treated surgically in 11, including repeat hepatectomy in 4. Of the 15 patients with adequate tissue for analysis, β-catenin immunostaining was positive in 7, with 4 corresponding CTNNB1 mutations associated with decreased survival; p53 staining was positive in 5 (4 with corresponding TP53 mutations). The median disease-free and overall survival after hepatectomy was 7 and 31.5 months, respectively, with a 5-year survival of 39%. In multivariate analysis, nonfunctional tumor and surgical treatment of recurrence were independent predictors of good outcome.
CONCLUSIONS: In selected patients with ACC LM, resection is associated with long-term survival and is, therefore, justified but rarely curative.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526905     DOI: 10.1245/s10434-012-2358-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  25 in total

1.  Actual 10-year survivors following resection of adrenocortical carcinoma.

Authors:  Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

Review 2.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

3.  An unusual case of adrenocortical carcinoma with liver metastasis that occurred at 23 years after surgery.

Authors:  Damien Bergeat; Michel Rayar; Luc Beuzit; Giovanni Battista Levi Sandri; Julien Dagher; Aude Merdrignac; Laetitia Tanguy; Karim Boudjema; Laurent Sulpice; Bernard Meunier
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

4.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

5.  Operative Management of Recurrent and Metastatic Adrenocortical Carcinoma: A Systematic Review.

Authors:  Winifred M Lo; Christine M Kariya; Jonathan M Hernandez
Journal:  Am Surg       Date:  2019-01-01       Impact factor: 0.688

Review 6.  Adrenocortical carcinoma: the management of metastatic disease.

Authors:  André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-04       Impact factor: 6.312

7.  Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study.

Authors:  Reed I Ayabe; Raja R Narayan; Samantha M Ruff; Michael M Wach; Winifred Lo; Pieter M H Nierop; Seth M Steinberg; R Taylor Ripley; Jeremy L Davis; Bas G Koerkamp; Michael I D'Angelica; T Peter Kingham; William R Jarnagin; Jonathan M Hernandez
Journal:  HPB (Oxford)       Date:  2019-08-22       Impact factor: 3.647

Review 8.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

9.  Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.

Authors:  Brian K Bednarski; Mouhammed Amir Habra; Alexandria Phan; Denai R Milton; Christopher Wood; Nicholas Vauthey; Douglas B Evans; Matthew H Katz; Chaan S Ng; Nancy D Perrier; Jeffrey E Lee; Elizabeth G Grubbs
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

10.  Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma.

Authors:  Thuy B Tran; Shishir K Maithel; Timothy M Pawlik; Tracy S Wang; Ioannis Hatzaras; John E Phay; Ryan C Fields; Sharon M Weber; Jason K Sicklick; Adam C Yopp; Quan-Yang Duh; Carmen C Solorzano; Konstantinos I Votanopoulos; George A Poultsides
Journal:  J Am Coll Surg       Date:  2016-09-13       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.